By Elric Langton | 29 January 2024
In a turn of events that was nearly eclipsed by the theatrics next door, Fresnillo's figures for Q4 '23 and the full fiscal year tiptoed into the spotlight, almost as if wearing ballet slippers on a creaky stage. It's a tale that almost got lost amidst the melodrama unfolding at our sister publication, Lemming Investor Research Newsletter. There, I was nearly entombed under a landslide of exertion, a sweat-induced rockslide, if you will, sparked by the shenanigans at SkinBioTherapeutics and Coral Products. It seems that in the world of junior markets, the more things change, the more they stay absurdly the same.
Further afield at Fresnillo Mine, nestled in the heart of Mexico's silver belt, the final quarter of 2023 was marked by the echoes of change. As the year drew to a close, it seemed Fresnillo peered into the abyss of their quarterly reports, only to find a narrative as twisted as the mine's own subterranean labyrinths.